
Medically Reviewed By
Dr. Neha Gupta ( Medical Oncology)
A clinical medical oncology guide on precision Biomarker-Driven Stomach Cancer Therapy, analyzing HER2 testing (ToGA / KEYNOTE-811), Claudin 18.2 monoclonal antibodies (Zolbetuximab - SPOTLIGHT trial), Nivolumab in PD-L1 CPS >=5 (CheckMate 649), and perioperative FLOT chemotherapy.
CRITICAL CLINICAL RED FLAG: Unexplained persistent dyspepsia, early satiety, progressive difficulty swallowing (dysphagia), iron deficiency anemia, or unintentional weight loss in an adult demands prompt upper gastrointestinal endoscopy and biopsy.
Advanced gastric adenocarcinoma requires upfront molecular testing on diagnostic endoscopic biopsy specimens to guide tailored systemic regimens:
HER2/neu Overexpression: Present in 15β20% of gastric adenocarcinomas (predominantly intestinal subtype and gastroesophageal junction tumors).
Claudin 18.2 Positivity: Expressed in up to 35β40% of gastric cancers (defined as >=75% of tumor cells showing moderate-to-strong membranous staining).
PD-L1 Combined Positive Score (CPS): Quantified via 28-8 or 22C3 IHC assays (CPS >=5 identifies major immunotherapy responders).
Microsatellite Instability-High (MSI-H / dMMR): Present in 5β8% of gastric tumors, exhibiting exceptional sensitivity to checkpoint inhibitors.
Biomarker-directed therapeutic algorithms:
HER2-Positive (KEYNOTE-811 Trial): Trastuzumab + Pembrolizumab + Fluoropyrimidine/Platinum doublet yields objective response rates exceeding 74%.
Claudin 18.2-Positive / HER2-Negative (SPOTLIGHT & GLOW Trials): Zolbetuximab (anti-Claudin 18.2 chimeric IgG1 antibody) + mFOLFOX6 or CAPOX significantly prolongs progression-free and overall survival.
PD-L1 CPS >=5 / HER2-Negative (CheckMate 649 Trial): Nivolumab + FOLFOX/CAPOX establishes standard frontline therapy, reducing mortality risk by 29%.
"Stomach cancer is no longer treated with one-size-fits-all chemotherapy. Comprehensive biomarker profiling for HER2, Claudin 18.2, and PD-L1 unlocks targeted therapies that dramatically improve survival." β Dr. Neha Gupta

For resectable cT2 or node-positive gastric cancer, 4 pre-operative and 4 post-operative cycles of FLOT (5-FU, Leucovorin, Oxaliplatin, Docetaxel) significantly improves complete R0 resection rates and 5-year survival compared to older ECF regimens.
CLINICAL CAUTION: HER2 testing in gastric cancer must follow gastric-specific scoring criteria (basolateral membrane staining and tumor heterogeneity); applying breast cancer HER2 criteria leads to false-negative under-treatment.
Following radical total or subtotal gastrectomy, routine lifelong intramuscular Vitamin B12 supplementation, oral iron, and small frequent high-protein meals prevent dumping syndrome and megaloblastic anemia.
1. Zolbetuximab plus mFOLFOX6 in Claudin 18.2-Positive Gastric Cancer (SPOTLIGHT Trial) β Lancet, 2023; 401(10389): 1655-1668.
2. First-line Nivolumab plus Chemotherapy for Advanced Gastric Cancer (CheckMate 649) β Lancet, 2021; 398(10294): 27-40.

Senior Consultant & Clinical Director β Medical Oncology
MBBS (BFUHS Faridkot), MD Radiation Oncology (BFUHS Faridkot), DrNB Medical Oncology (Sarvodaya Hospital, Faridabad), Precision Oncology (Harvard, USA), Ex Consultant RGCI New Delhi

13+ Years Experience
Spica β Grover Hospital
Request a priority OPD appointment or second opinion on your scans.
Proprietary surgical methodologies and precision protocols pioneered by our senior directors to minimize trauma, protect natural anatomy, and accelerate recovery.

Dr. Deepak Garg (Orthopaedic Surgical Oncology - RGCI Delhi Trained) and Dr. Neha Gupta (Medical Oncology) co-lead the Bone Cancer & Sarcoma Center at Spica Healthcare. Integrating intensive multi-agent neoadjuvant chemotherapy protocols (MAP: High-Dose Methotrexate, Doxorubicin, Cisplatin for Osteosarcoma; VIDE: Vincristine, Ifosfamide, Doxorubicin, Etoposide for Ewing Sarcoma) with 3D computer-navigated limb salvage surgery and modular titanium megaprosthetic joint reconstruction, 5-year survival rates exceed 75% to 80% while saving over 95% of patients from limb amputation.
Spica Healthcare β Bone and Cancer Institute, Bathinda β is South-Western Punjab's premier super-speciality centre led by AIIMS and Tata Memorial fellowship-trained directors.
Every diagnostic MRI review, surgical staging, and operation is personally directed by chief clinical specialists β Dr. Deepak Garg (Orthopaedic Oncology & Robotics) and Dr. Neha Gupta (Medical Oncology) β guaranteeing zero junior proxies.
Sub-millimeter implant positioning and soft-tissue ligament balancing ensuring patients walk comfortably within 24 hours of total knee replacement.
South-West Punjab's only dedicated centre for modular titanium megaprosthesis, saving natural limbs and functions in 95%+ of bone cancer patients.
Full cashless coverage for Ayushman Bharat (PM-JAY), Punjab Govt Health Schemes, ECHS, and 30+ private insurance networks with on-desk approvals.
Positive-pressure HEPA filtered theatres minimizing infection rates below international benchmarks with 24/7 dedicated critical care backup.
Fellowship-trained surgical directors from AIIMS & Tata Memorial providing compassionate, world-class tertiary care in super-speciality orthopaedics and medical oncology.

Senior Consultant & Clinical Director β Medical Oncology
MBBS (BFUHS Faridkot), MD Radiation Oncology (BFUHS Faridkot), DrNB Medical Oncology (Sarvodaya Hospital, Faridabad), Precision Oncology (Harvard, USA), Ex Consultant RGCI New Delhi


Senior Consultant & Clinical Director β Orthopaedic Oncology & Robotic Joint Surgery
16+ Yrs ExpSenior Consultant & Clinical Director β Orthopaedic Oncology & Robotic Joint Surgery
MBBS (TNMC Mumbai), DNB Orthopaedics (PGI & SP Miraj), Fellowship Arthroplasty and Arthroscopy (Fortis Hospital, New Delhi), Fellowship Orthopaedic Oncology (Rajiv Gandhi Cancer Institute, New Delhi)
Free OPD screening camps, director-led masterclasses, and national oncology representations by Spica Healthcare.
Real stories from patients who recovered through limb preservation surgery, 3D robotic joint replacements, and precision cancer care at Spica Healthcare β Grover Hospital, Bathinda.
Evidence-based surgical recovery roadmaps, robotic joint protocols, and precision oncology insights written by our clinical directors.